Johnson & Johnson innovation center has reached 12 new alliances around the world

Source: Biovalley, June 23, 2014, Johnson & Johnson (JNJ) announced on June 19 that it has reached 12 new alliances with life science companies and scientific research institutions all over the world to explore early innovation in a wide range of treatment fields and across pharmaceutical, medical equipment, diagnosis and consumer health care fields Paul Stoffels, Johnson & Johnson's chief scientific officer and President of global pharmaceutical, said that the future of healthcare will be defined by pharmaceutical companies, academic institutions and government departments The three parties will work together and make full use of the existing advantages to try new ways of innovation while thinking about the current model Since its launch more than a year ago, Johnson & Johnson innovation center is working with global life science researchers and entrepreneurs to identify exciting early technologies and turn them into patient solutions The early collaboration announced today represents the recent R & D alliance of innovation centers in Boston, California and London, as well as exciting new technologies such as 3D Printing technology is used for orthopedic trauma, creating new brown fat for metabolic diseases, and promoting new science in the field of diseases whose medical needs are significantly not met, such as lymphoma, rheumatoid arthritis, prostate cancer, dementia, Alzheimer's disease, diabetes, insomnia The cooperation includes: 1 Using promising new methods to treat cancer: for lymphoma, Janssen biotechnology and JNJ innovation have reached a cooperation with Weill Cornell Medical College to develop a protein that can target compounds to cause lymphangioma New immunotherapy for prostate cancer - Janssen biotechnology and JNJ innovation have reached a global exclusive license with aduro biotechnology to develop new immunotherapy for prostate cancer 2 Patient specific 3-D printing for orthopedic needs: 3-D printing for absorbable implants - DePuy and Johnson & Johnson innovation have reached a strategic partnership with medical equipment company tissue regeneration systems (TRS) to help develop patient specific, absorbable implants for the treatment of large bone defects in trauma and orthopedic oncology This cooperation will integrate DePuy's proprietary technology and market leadership with TRS's 3D printing technology and development expertise The cooperation also includes a series of development opportunities for other applications 3 Promote the progress of Alzheimer's disease and neuroscience: accelerate the research progress of Alzheimer's disease - neuroscience of Janssen research and development company will cooperate with dementias research platform (DRP) in the UK DRP is an important initiative of the Medical Research Council (MRC) in the UK It aims to accelerate the research progress of dementia by coordinating public-private partnerships with six companies and eight leading academic institutions At the level of induction sedation, Johnson & Johnson's Ethicon endo surery company has reached a research cooperation with brainstem biometrics company, and will jointly fund to determine the clinical and operational availability of a small, non-invasive medical device sensor, tremor monitor unit, which can be used to detect minute eye movement in patients undergoing anesthesia As a possible biomarker of basic brainstem function, this technique has the potential to distinguish between sedative safety and unsafe level Insomnia - neuroscience of Janssen Pharmaceutical, Johnson & Johnson innovation and Janssen R & D Co., Ltd has reached a research cooperation with Minerva neurosciences to develop an orexin-2 receptor antagonist min-202 for the treatment of primary and secondary insomnia and other related neurological diseases Epigenetic regulation of central nervous system: Johnson & Johnson Development Co., Ltd has participated in Rodin therapeutics and a series of equity investment of Johnson & Johnson innovation Rodin is committed to discovering epigenetic modulators for the treatment of cognitive disorders (including Alzheimer's disease) 4 Seeking new methods to treat diabetes and cardiovascular diseases: to create new brown fat -- Janssen Pharmaceutical and Johnson & Johnson innovation have reached a cooperation with energesis pharmaceutical to identify the biological compounds that can stimulate the formation of brown fat (BAT) for the treatment of metabolic diseases Energesis's new approach takes advantage of recent scientific discoveries in bat biology to enhance the body's ability to burn stored fat and reduce insulin resistance Nutrition induction pathway - Johnson & Johnson development company has participated in equity investment of navitor pharmaceutical and Johnson & Johnson innovation Navitor is developing a highly specific mTORC1 modulator, which is responsible for cell response to available nutrients, including cell growth and function Navitor is taking advantage of the central importance of mTORC1 pathway to develop new therapies for metabolic diseases such as diabetes, as well as autoimmune, musculoskeletal and other diseases Heart remodeling - Johnson & Johnson development has participated in equity investment of ascelegen therapeutics and Johnson & Johnson innovation Ascelegen is developing novel treatment-related growth factors for cardiovascular disease, including heart failure Ascelegen's work was based on the gdf-11 study conducted jointly by the Harvard Stem Cell Institute and Brigham and women's hospital 5 For autoimmune diseases: stop the production of autoantigen in rheumatoid arthritis and other autoimmune diseases - Johnson & Johnson development company has participated in equity investment of padlock therapeutics and Johnson & Johnson innovation Padlock is developing novel therapies for targeting arginine deaminase, an enzyme that mediates protein citrullination Protein citrullination can lead to the production of strong autoantigens, participate in the earliest events leading to rheumatoid arthritis, and drive the formation of inflammation and immune complexes in active autoimmune diseases 6 A new strategy in the field of skin, oral and respiratory diseases: exploring the impact of Microbiome on health and disease - Johnson consumer company and Johnson innovation have worked with University of Manchester to explore the potential of probiotics extracts for the prevention and treatment of skin, oral and respiratory diseases The agreement highlights Johnson & Johnson innovation's approach to creating research collaboration across pharmaceutical, medical devices, diagnostic and consumer business areas Last year, JNJ innovation launched its innovation center and established four regional hubs to identify scientific opportunities with the potential to advance new medical solutions Through the innovation center, external innovators can obtain a wide range of internal resources, including capital, R & D expertise and incubation At present, the offices in Boston, London and California have been fully operational The fourth office in Shanghai, China has now set up a small but growing scientific team, which will be officially opened in 2014 to carry out R & D cooperation throughout the Asia Pacific region.